Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic-Reference-Cited by-同舟云学术

Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic

Published:2020-09-04 Issue:17 Volume:4 Page:4147-4150
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Purtill Duncan¹²^ORCID,Antonenas Vicki³,Chiappini Paul⁴,Tong Daochen³,O’Flaherty Elizabeth⁴⁵,Bajel Ashish⁴⁵,Kabani Karieshma⁶,Larsen Stephen⁶⁷,Tan Suikeat⁸,Hutchins Cheryl⁹,Curtis David J.¹⁰¹¹^ORCID,Kennedy Glen A.⁹,Watson Anne-Marie¹²,Bai LiJun¹³,Greenwood Matthew⁷¹³,Gottlieb David J.³⁷,Hamad Nada⁸¹⁴^ORCID

Affiliation:

1. Fiona Stanley Hospital, Murdoch, WA, Australia;

2. PathWest Laboratory Medicine, Murdoch, WA, Australia;

3. Westmead Hospital, Sydney, NSW, Australia;

4. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;

5. The Royal Melbourne Hospital, Melbourne, VIC, Australia;

6. Royal Prince Alfred Hospital, Sydney, NSW, Australia;

7. Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia;

8. St Vincent’s Hospital, Darlinghurst, NSW, Australia;

9. Royal Brisbane and Woman’s Hospital, Herston, QLD, Australia;

10. Alfred Health, Melbourne, VIC, Australia;

11. Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia;

12. Liverpool Hospital, Liverpool, NSW, Australia;

13. Royal North Shore Hospital, St Leonards, NSW, Australia; and

14. Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia

Abstract

Abstract Donor registries and transplantation societies recommend cryopreservation of unrelated donor hemopoietic progenitor cell (HPC) products before the recipient commences conditioning therapy to mitigate the donor and travel risks associated with the COVID-19 pandemic. However, little is known regarding the postthaw quality of such allogeneic products or the effect of precryopreservation storage and processing on these characteristics. We investigated the postthaw CD34+ cell recovery and viability of 305 allogeneic HPC products cryopreserved at 9 laboratories across Australia. Median postthaw CD34+ cell recovery was 76% and ranged from 6% to 122%. Longer transit time before cryopreservation, white cell count (WCC) during storage, and complex product manipulation before cryopreservation were independently associated with inferior postthaw CD34+ cell recovery. Longer precryopreservation transit time and WCC were also associated with inferior postthaw CD34+ cell viability. We conclude that although postthaw CD34+ cell recovery and viability of cryopreserved allogeneic HPC is generally acceptable, there is a significant risk of poor postthaw product quality, associated with prolonged storage time, higher WCC, and complex product manipulation precryopreservation. Awareness of expected postthaw recovery and practices that influence it will assist collection, processing, and transplant centers in optimizing outcomes for transplant recipients.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/4/17/4147/1757092/advancesadv2020002431.pdf

Reference13 articles.

1. European Society for Blood and Marrow Transplantation. Coronavirus disease COVID-19: EBMT recommendations update April 21, 2020 Available at: https://www.ebmt.org/sites/default/files/2020-04/EBMT_COVID-19-guidelines_v.7.1%282020-04-21%29.pdf. Accessed 29 April 2020.

2. National Marrow Donor Program: BeTheMatch. Donor Product Cryopreservation: updated March 23, 2020. Available at: https://www.ebmt.org/sites/default/files/2020-04/EBMT_COVID-19-guidelines_v.7.1%282020-04-21%29.pdf. Accessed 29 April 2020.

3. Hamad N . Bone Marrow Transplant Society of Australia and New Zealand COVID19 Consensus Position Statement 15th April 2020. Available at: https://www.bmtsanz.org.au/bone-marrow-transplant-society-of-australia-and-new-zealand-covid19-consensus-position-statement-15th-april-2020/. Accessed 29 April 2020.

4. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts;Avery;Blood,2011

5. Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice;Purtill;Blood,2014

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid Storage of Peripheral Blood Stem Cell Products: Effects of Time and Temperature on Product Quality;Transplantation and Cellular Therapy;2024-01

2. Automatic generation of alloreactivity-reduced donor lymphocytes and hematopoietic stem cells from the same mobilized apheresis product;Journal of Translational Medicine;2023-11-25

3. Cryopreservation of Growth Factor-Mobilized Peripheral Blood Stem Cells Does Not Compromise Major Outcomes after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience;Transplantation and Cellular Therapy;2023-11

4. Variable recovery of cryopreserved hematopoietic stem cells and leukocyte subpopulations in leukapheresis products;Transfusion and Apheresis Science;2023-10

5. Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP);Bone Marrow Transplantation;2023-09-06